How I treat medullary thyroid cancer

Cabanillas, 2016, Thyroid cancer, Lancet, 388, 2783, 10.1016/S0140-6736(16)30172-6 Filetti, 2019, Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 1856, 10.1093/annonc/mdz400 Roy, 2013, Current understanding and management of medullary thyroid cancer, Oncologist, 18, 1093, 10.1634/theoncologist.2013-0053 Ceolin, 2019, Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives, Endocr Relat Cancer, 26, R499, 10.1530/ERC-18-0574 Meijer, 2010, Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis, Clin Endocrinol (Oxf), 72, 534, 10.1111/j.1365-2265.2009.03666.x Cheung, 2008, Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis, J Clin Endocrinol Metab, 93, 2173, 10.1210/jc.2007-2496 Vierhapper, 2005, Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders, Thyroid, 15, 1267, 10.1089/thy.2005.15.1267 Niederle, 2018, Calcium-stimulated calcitonin – the “new standard” in the diagnosis of thyroid C-cell disease – clinically relevant gender-specific cut-off levels for an “old test”, Biochem Med (Zagreb), 28, 030710, 10.11613/BM.2018.030710 Niederle, 2020, Early diagnosis of medullary thyroid cancer: are calcitonin stimulation tests still indicated in the era of highly sensitive calcitonin immunoassays?, Thyroid, 30, 974, 10.1089/thy.2019.0785 Kaserer, 2001, Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients, Am J Surg Pathol, 25, 1245, 10.1097/00000478-200110000-00004 Niederle, 2021, Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction, Br J Surg, 108, 174, 10.1093/bjs/znaa047 Wells, 2012, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial, J Clin Oncol, 30, 134, 10.1200/JCO.2011.35.5040 Kreissl, 2020, Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial, J Clin Oncol, 38, 2773, 10.1200/JCO.19.02790 Elisei, 2013, Cabozantinib in progressive medullary thyroid cancer, J Clin Oncol, 31, 3639, 10.1200/JCO.2012.48.4659 Schlumberger, 2017, Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma, Ann Oncol, 28, 2813, 10.1093/annonc/mdx479 Wirth, 2020, Efficacy of selpercatinib in RET-altered thyroid cancers, N Engl J Med, 383, 825, 10.1056/NEJMoa2005651 Koehler, 2021, Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer, Thyroid, 31, 459, 10.1089/thy.2020.0206 Belli, 2021, ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research, Ann Oncol, 32, 337, 10.1016/j.annonc.2020.11.021 Maxwell, 2014, Medical management of metastatic medullary thyroid cancer, Cancer, 120, 3287, 10.1002/cncr.28858 Hadoux, 2016, Management of advanced medullary thyroid cancer, Lancet Diabetes Endocrinol, 4, 64, 10.1016/S2213-8587(15)00337-X Parghane, 2020, Clinical utility of 177Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity, Head Neck, 42, 401, 10.1002/hed.26024 Nelkin, 2017, Recent advances in the biology and therapy of medullary thyroid carcinoma, F1000Res, 6, 2184, 10.12688/f1000research.12645.1